Adenosine amine congener (ADAC) is a novel and selective A1 adenosine receptor agonist that can ameliorate noise- and Cisplatin-induced cochlear injury. Adenosine amine congener also has neuroprotective effects.
Physicochemical Properties
| Molecular Formula | C28H32N8O6.H2O |
| Molecular Weight | 594.61896 |
| Exact Mass | 576.244 |
| Elemental Analysis | C, 58.32; H, 5.59; N, 19.43; O, 16.65 |
| CAS # | 96760-69-9 |
| PubChem CID | 126054 |
| Appearance | Solid powder |
| LogP | 1.217 |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 11 |
| Heavy Atom Count | 42 |
| Complexity | 887 |
| Defined Atom Stereocenter Count | 4 |
| SMILES | OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C(N=CN=C32)NC4=CC=C(CC(NC5=CC=C(CC(NCCN)=O)C=C5)=O)C=C4)O1)O)O |
| InChi Key | JFRJCQJVFMHZOO-QZHHGCDDSA-N |
| InChi Code | InChI=1S/C28H32N8O6/c29-9-10-30-21(38)11-16-1-5-18(6-2-16)34-22(39)12-17-3-7-19(8-4-17)35-26-23-27(32-14-31-26)36(15-33-23)28-25(41)24(40)20(13-37)42-28/h1-8,14-15,20,24-25,28,37,40-41H,9-13,29H2,(H,30,38)(H,34,39)(H,31,32,35)/t20-,24-,25-,28-/m1/s1 |
| Chemical Name | N-(2-aminoethyl)-2-[4-[[2-[4-[[9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]amino]phenyl]acetyl]amino]phenyl]acetamide |
| Synonyms | Adenosine amine congener; 6-Adac; ADAC. |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Adenosylamine homologs lessen oxidative damage in cochlea exposed to noise, protecting sensory hair cells. In cochlear tissue, adenosylamine homologs also lessen cisplatin-induced apoptosis, particularly in sensory hair cells and striatal border cells. Adenosylamine homologues have otoprotective properties that block the release of glutamate via presynaptic A1 receptors and voltage-gated Ca2+ channel inhibition, which prevents the activation of the pathways leading to necrotic and apoptotic cell death [1]. |
| ln Vivo | Treatment with adenosylamine congener (25-300 μg/kg/day; i.p.; daily; for 5 days; male Wistar rats) is most effective in the first 24 hours following noise exposure at dosages >50 μg/kg; it offers protection of up to 21 dB. Adenosylamine congeners have a dose- and time-dependent effect on mitigating noise-induced hearing loss [1]. |
| Animal Protocol |
Animal/Disease Models: Male Wistar rats (8-10 weeks old) received noise exposure treatment [1] Doses: 25 μg/kg/day, 50 μg/kg/day, 100 μg/kg/day, 200 μg/kg/day , 300 μg/kg/day Doses: intraperitoneal (ip) injection; daily; for 5 days Experimental Results: Most effective in the first 24 hrs (hrs (hours)) after noise exposure at doses >50 μg/kg and provided up to 21 dB of protection (8- average over the 28 kHz range). |
| References |
[1]. Adenosine amine congener as a cochlear rescue agent. Biomed Res Int. 2014;2014:841489. [2]. Adenosine amine congener mitigates noise-induced cochlear injury. Purinergic Signal. 2010 Jun;6(2):273-81. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~31.25 mg/mL (~54.20 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (3.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6817 mL | 8.4087 mL | 16.8175 mL | |
| 5 mM | 0.3363 mL | 1.6817 mL | 3.3635 mL | |
| 10 mM | 0.1682 mL | 0.8409 mL | 1.6817 mL |